How have MTEM shares performed in 2024?

Molecular Templates' stock was trading at $3.73 on January 1st, 2024. Since then, MTEM stock has decreased by 60.2% and is now trading at $1.4850. View the best growth stocks for 2024 here .

Are investors shorting Molecular Templates?

Molecular Templates saw a increase in short interest in March. As of March 31st, there was short interest totaling 33,800 shares, an increase of 23.8% from the March 15th total of 27,300 shares. Based on an average daily volume of 52,300 shares, the days-to-cover ratio is presently 0.6 days. Currently, 1.2% of the shares of the company are sold short. View Molecular Templates' Short Interest .

When is Molecular Templates' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our MTEM earnings forecast .

How were Molecular Templates' earnings last quarter?

Molecular Templates, Inc. (NASDAQ:MTEM) announced its earnings results on Monday, November, 15th. The biotechnology company reported ($8.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.67) by $2.43. The biotechnology company earned $2.38 million during the quarter, compared to the consensus estimate of $15.69 million. Molecular Templates had a negative net margin of 14.18% and a negative trailing twelve-month return on equity of 9,335.53%.

When did Molecular Templates' stock split?

Molecular Templates shares reverse split on Monday, August 14th 2023. The 1-15 reverse split was announced on Friday, August 11th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Molecular Templates own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Molecular Templates investors own include ZIOPHARM Oncology (ZIOP) , Novavax (NVAX) , Gilead Sciences (GILD) , TG Therapeutics (TGTX) , Pfizer (PFE) , Synergy Pharmaceuticals (SGYP) , Amarin (AMRN) , Corbus Pharmaceuticals (CRBP) and Exelixis (EXEL) .

How do I buy shares of Molecular Templates?

Shares of MTEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:MTEM

Molecular Templates (MTEM) Stock Price, News & Analysis

→ Now Open: Crypto emergency update (From InvestorPlace) (Ad)

Free MTEM Stock Alerts

$1.48

-0.09 (-5.71%)

(As of 04/18/2024 ET)

Compare

Today's Range: $1.45
▼
$1.57
50-Day Range: $1.49
▼
$4.03
52-Week Range: $1.45
▼
$9.45

Volume: 36,641 shs
Average Volume: 54,187 shs
Market Capitalization: $7.98 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Molecular Templates alerts:

Molecular Templates MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
1.15% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.93
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Acquiring Shares
$587,500 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.70) to ($2.85) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.11 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Molecular Templates.

3.0

Short Interest

Percentage of Shares Shorted
1.15% of the float of Molecular Templates has been sold short.
Short Interest Ratio / Days to Cover
Molecular Templates has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Molecular Templates has recently increased by 23.81%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Molecular Templates does not currently pay a dividend.
Dividend Growth
Molecular Templates does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Molecular Templates has received a 72.55% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Molecular Templates is -0.93.

0.6

News and Social Media Coverage

Search Interest
Only 2 people have searched for MTEM on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
2 people have added Molecular Templates to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Molecular Templates insiders have bought more of their company's stock than they have sold. Specifically, they have bought $587,500.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
13.40% of the stock of Molecular Templates is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
95.47% of the stock of Molecular Templates is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Molecular Templates are expected to decrease in the coming year, from ($2.70) to ($2.85) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Molecular Templates is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Molecular Templates is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Molecular Templates has a P/B Ratio of 1.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Molecular Templates Stock (NASDAQ:MTEM)

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company primarily develops therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

MTEM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MTEM Stock News Headlines

April 5, 2024 | insidertrades.com

Target N. V. Biotech Acquires 250,000 Shares of Molecular Templates, Inc. (NASDAQ:MTEM) Stock

April 11, 2024 | uk.investing.com

Molecular Templates reports progress in cancer therapy trial

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 11, 2024 | msn.com

MTEM Stock Earnings: Molecular Templates Beats EPS, Misses Revenue for Q4 2023

April 9, 2024 | msn.com

What's Going On With Molecular Templates Stock?

April 9, 2024 | globenewswire.com

Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism

March 29, 2024 | msn.com

Molecular Templates GAAP EPS of -$0.73, revenue of $7.02M

March 29, 2024 | globenewswire.com

Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 28, 2024 | globenewswire.com

Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement

March 4, 2024 | finance.yahoo.com

Molecular Templates, Inc. Provides Interim Update

March 4, 2024 | globenewswire.com

Molecular Templates, Inc. Provides Interim Update

February 8, 2024 | finance.yahoo.com

Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

December 6, 2023 | morningstar.com

Molecular Templates Inc MTEM

November 13, 2023 | msn.com

Molecular Templates GAAP EPS of -$0.82 beats by $1.13, revenue of $6.8M beats by $4.34M

November 13, 2023 | finance.yahoo.com

Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update

November 1, 2023 | finance.yahoo.com

Molecular Templates to Participate in Upcoming Investor Conferences

September 30, 2023 | seekingalpha.com

Molecular Templates appoints Maurizio Voi as chief medical officer

September 30, 2023 | finanznachrichten.de

Molecular Templates, Inc.: Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer

September 28, 2023 | finance.yahoo.com

Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer

August 31, 2023 | msn.com

Molecular Templates (MTEM) Price Target Increased by 1400.00% to 38.25

August 11, 2023 | finanznachrichten.de

Molecular Templates, Inc.: Molecular Templates Announces 1-for-15 Reverse Stock Split

August 11, 2023 | finance.yahoo.com

Molecular Templates Announces 1-for-15 Reverse Stock Split

August 10, 2023 | msn.com

Molecular Templates GAAP EPS of -$0.19 beats by $0.15, revenue of $6.87M beats by $4.29M

August 10, 2023 | finance.yahoo.com

Molecular Templates, Inc. Reports Second Quarter 2023 Financial Results and Business Update

August 4, 2023 | finance.yahoo.com

After layoffs, Molecular Templates overhauls C-suite

July 13, 2023 | seekingalpha.com

Molecular Templates launches $40M private placement

See More Headlines

Receive MTEM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Molecular Templates and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/15/2021
Today: 4/18/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:MTEM
CUSIP: 88580720
CIK: 1183765
Web: www.mtem.com
Phone: (512) 869-1555
Fax: 650-474-2529
Employees: 111
Year Founded: 2009

Profitability

EPS (Most Recent Fiscal Year): ($1.55)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-8,120,000.00
Net Margins: -14.18%
Pretax Margin: -14.20%
Return on Equity: -9,335.53%
Return on Assets: -20.51%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.97
Quick Ratio: 0.97

Sales & Book Value

Annual Sales: $52.63 million
Price / Sales: 0.15
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.78 per share
Price / Book: 1.90

Miscellaneous

Outstanding Shares: 5,374,000
Free Float: 4,369,000
Market Cap: $7.98 million
Optionable: No Data
Beta: 1.15

Social Links

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Dr. Eric E. Poma Ph.D. (Age 52)
CEO, Chief Scientific Officer & Director
Comp: $923.34k
Ms. Jason S Kim (Age 49)
President, CFO, Treasurer & Principal Accounting Officer
Comp: $639.85k
Ms. Kristen Quigley B.A. (Age 53)
Chief Operating Officer
Dr. Grace Kim
Chief Strategy Officer & Head of IR
Dr. Joseph Phillips Ph.D.
Senior VP & Head of CMC Development
Dr. Maurizio Voi M.D. (Age 66)
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MTEM Stock Analysis - Frequently Asked Questions

How have MTEM shares performed in 2024?: Molecular Templates' stock was trading at $3.73 on January 1st, 2024. Since then, MTEM stock has decreased by 60.2% and is now trading at $1.4850.
View the best growth stocks for 2024 here.
Are investors shorting Molecular Templates?: Molecular Templates saw a increase in short interest in March. As of March 31st, there was short interest totaling 33,800 shares, an increase of 23.8% from the March 15th total of 27,300 shares. Based on an average daily volume of 52,300 shares, the days-to-cover ratio is presently 0.6 days. Currently, 1.2% of the shares of the company are sold short.
View Molecular Templates' Short Interest.
When is Molecular Templates' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our MTEM earnings forecast.
How were Molecular Templates' earnings last quarter?: Molecular Templates, Inc. (NASDAQ:MTEM) announced its earnings results on Monday, November, 15th. The biotechnology company reported ($8.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.67) by $2.43. The biotechnology company earned $2.38 million during the quarter, compared to the consensus estimate of $15.69 million. Molecular Templates had a negative net margin of 14.18% and a negative trailing twelve-month return on equity of 9,335.53%.

When did Molecular Templates' stock split?: Molecular Templates shares reverse split on Monday, August 14th 2023. The 1-15 reverse split was announced on Friday, August 11th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
What other stocks do shareholders of Molecular Templates own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Molecular Templates investors own include ZIOPHARM Oncology (ZIOP), Novavax (NVAX), Gilead Sciences (GILD), TG Therapeutics (TGTX), Pfizer (PFE), Synergy Pharmaceuticals (SGYP), Amarin (AMRN), Corbus Pharmaceuticals (CRBP) and Exelixis (EXEL).
How do I buy shares of Molecular Templates?: Shares of MTEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MTEM) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial